Trans-sodium crocetinate (TSC) is a novel synthetic carotenoid compound that improves diffusion of small molecules including oxygen in solutions. TSC provides neuroprotection in healthy rats and rabbits. We determine whether TSC is neuroprotective in obese mice. Sixteen-week old CD-1 male mice fed with high fat diet for the last 10 weeks were subjected to a 90-min middle cerebral arterial occlusion (MCAO). They received TSC by two boluses through a tail vein at 10 min after the onset of MCAO and reperfusion, respectively, with a total dose of 0.14, 0.28 and 0.7 mg/kg or by a bolus-infusion-bolus strategy with a total dose of 0.14 mg/kg during MCAO. Neurological outcome was evaluated 72 h after MCAO. Brain tissues were harvested at 24 h after MCAO to measure nitrotyrosine containing proteins, 4-hydroxy-2-nonenal, matrix metalloproteinase (MMP)-2 and -9 activity and expression, and inflammatory cytokines. TSC given by the two-bolus strategy did not improve neurological outcome. The bolus-infusion-bolus strategy significantly reduced brain edema, infarct volume and hemorrhagic transformation and improved neurological functions. TSC reduced nitrotyrosine containing proteins, MMP-9 activity and expression, and inflammatory cytokines in the ischemic brain tissues. Our results indicate that TSC delivered by the bolus-infusion-bolus strategy provides neuroprotection in obese mice. This protection may be through reduction of oxidative stress, MMP-9 activity and inflammatory cytokines in the ischemic brain tissues.